Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 15/20 | 0.69 |
| ▸ | JAK3 | P52333 | 9/20 | 0.69 |
| ▸ | CDK2 | P24941 | 2/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | JAK1 | P23458 | 4/20 | 0.49 |
| ▸ | IKBKB | O14920 | 3/20 | 0.49 |
| ▸ | CHUK | O15111 | 2/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.49 |
| ▸ | FLT3 | P36888 | 2/20 | 0.49 |
| ▸ | TYK2 | P29597 | 2/20 | 0.49 |
| ▸ | KIT | P10721 | 1/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.49 |
| ▸ | FLT1 | P17948 | 1/20 | 0.49 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.49 |
| ▸ | FLT4 | P35916 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.49 |
| ▸ | PLK4 | O00444 | 1/20 | 0.49 |
| ▸ | CIT | O14578 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4383899 | 1.00 | JAK2 (0.69) | JAK2JAK3CDK2HDAC1HDAC6 | |
| SCHEMBL4379462 | 0.90 | JAK2 (0.68) | JAK2JAK3CDK2HDAC1HDAC6 | |
| SCHEMBL8238623 | 0.88 | JAK2 (0.76) | JAK2JAK3CDK2HDAC1HDAC6 | |
| SCHEMBL4381852 | 0.87 | JAK2 (0.59) | JAK2JAK3HDAC1HDAC6JAK1 | |
| SCHEMBL4383748 | 0.87 | JAK2 (0.55) | JAK2JAK3HDAC1HDAC6JAK1 | |
| SCHEMBL4376827 | 0.87 | JAK2 (0.54) | JAK2JAK3CDK2HDAC1HDAC6 | |
| SCHEMBL4382382 | 0.86 | JAK2 (0.63) | JAK2JAK3HDAC1HDAC6JAK1 | |
| SCHEMBL4374501 | 0.86 | JAK2 (0.72) | JAK2JAK3CDK2HDAC1HDAC6 | |
| SCHEMBL4384208 | 0.86 | JAK2 (0.72) | JAK2JAK3CDK2HDAC1HDAC6 | |
| SCHEMBL4378264 | 0.86 | JAK2 (0.80) | JAK2JAK3CDK2HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440663-B2 | 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20090298830-A1 | 4-Aryl-2-Amino-Pyrimidnes or 4-Aryl-2-Aminoalkyl-Pyrimidines as Jak-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298830-A1 | 4-Aryl-2-Amino-Pyrimidnes or 4-Aryl-2-Aminoalkyl-Pyrimidines as Jak-2 Modulators and Methods of Use | JAK2, JAK1, JAK3 | JAK2 1/4885JAK3 3/4885CDK2 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.